|1.||Pidde-Queiroz, Giselle: 1 article (07/2013)|
|2.||Venancio, Emerson J: 1 article (07/2013)|
|3.||Carvalho, Daniela Cajado: 1 article (07/2013)|
|4.||Kuniyoshi, Alexandre K: 1 article (07/2013)|
|5.||Tambourgi, Denise V: 1 article (07/2013)|
|6.||Portaro, Fernanda C V: 1 article (07/2013)|
|7.||Zhang, Jing: 1 article (06/2011)|
|8.||Hao, Fang: 1 article (06/2011)|
|9.||Liang, Jin-Ying: 1 article (06/2011)|
|10.||Qiu, Pei-Yong: 1 article (06/2011)|
03/15/1991 - "Dynorphin A(1-13) administered intrathecally to rats induces a reversible hindlimb paralysis and permanent loss of the tail-flick reflex in a dose-dependent and all-or-none manner. "
03/15/1991 - "In the present studies, we examined whether repeated injections of dynorphin A(1-13) acetate salt could change the characteristics of the reversible paralysis. "
03/15/1991 - "We conclude that the reversible paralysis induced by dynorphin A(1-13) is repeatable which suggests that the paralysis results from nontoxic or subtoxic actions of dynorphin. "
06/01/1995 - "Dynorphin A(1-13) has little toxicity when administered at modest doses IV but has been reported to cause hindlimb paralysis and necrosis of the spinal cord in rats, at the catheter tip, when administered intrathecally. "
01/01/1995 - "In an earlier study, dynorphin A(1-13) [Dyn A(1-13)] was shown to inhibit heat-induced edema in the anesthetized rat's paw but the potency of this action was low, with effective doses in the range of 3-4 mg/kg i.v. In this study, Dyn A and related fragments were tested. "
11/01/1987 - "Ovine-CRF and dynorphin A(1-13) injected i.v. inhibited the protein extravasation and edema induced by 58 degrees C water, but morphine, ethylketocyclazocine and FK 33,824 (a stabilized enkephalin analog) were not active at this temperature. "
|3.||Substance-Related Disorders (Drug Abuse)
03/01/1999 - "Twelve healthy subjects with no history of substance abuse participated in a placebo-controlled single-blinded study of subjective response to acute i.v. administration of placebo and two doses of the natural shortened peptide sequence of the kappa-opioid agonist, dynorphin A(1-13) (low dose 120 micrograms/kg, high dose 500 micrograms/kg). "
|4.||Hypotension (Low Blood Pressure)
12/01/1984 - "Additionally, pretreatment with dynorphin 1-13 prevented the subsequent reversal of endotoxemic hypotension by ICI 174864. "
12/01/1984 - "ICI 174864, a putative delta opioid antagonist, reverses endotoxemic hypotension: pretreatment with dynorphin 1-13, A kappa agonist, blocks this action."
10/01/1991 - "Following central administration of antisera against beta- and alpha-endorphin and dynorphin A(1-13), the amount of blood that had to be withdrawn to induce hypotension was elevated. "
07/01/2013 - "The detection of metalloproteinase(s) with specificity for both dynorphin 1-13 degradation and leu-enkephalin releasing can be important for the mechanistic understanding of hypotension and bradycardia induction in cases of scorpion stings, whereas hyaluronidases might contribute to the diffusion of the toxins present in these venoms. "
09/25/1989 - "In addition, the local injection into the NTS of a beta-endorphin antiserum but not of antisera against [Met5]enkephalin and dynorphin A(1-13) prevented the alpha-methyldopa-induced hypotension. "
12/01/1996 - "administration of dynorphin A(1-13) or dynorphin A(2-17) or dynorphin A(2-13) also produced long-lasting tactile allodynia. "
04/01/1999 - "Coadministration of three kappa opioid ligands, U50,488 (3.2-100 microgram), bremazocine (0.1-3.2 microgram), and dynorphin A(1-13) (3.2-100 microgram), with capsaicin in the tail dose-dependently inhibited capsaicin-induced allodynia. "
|2.||Morphine (MS Contin)
|4.||beta-Endorphin (Endorphin, beta)
|5.||Immune Sera (Antisera)
|7.||Opioid Peptides (Opioid Peptide)
|3.||Indwelling Catheters (Arterial Line)